Want to see HAE full AI Analyst Report?

Haemonetics (HAE) Stock Forecast & Price Target

442 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HAE Analyst Ratings

Moderate Buy

6 Buy

3 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Haemonetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HAE Stock 12 Month Forecast

Average Price Target

$104.88

▼(-0.12% Downside)

Based on 9 Wall Street analysts offering 12 month price targets for Haemonetics in the last 3 months. The average price target is $104.88 with a high forecast of $125.00 and a low forecast of $84.00. The average price target represents a -0.12% change from the last price of $105.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"47":"$47","126":"$126","66.75":"$66.8","86.5":"$86.5","106.25":"$106.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":104.875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$104.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$84.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[47,66.75,86.5,106.25,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,101.95,103.72307692307693,105.49615384615385,107.26923076923077,109.04230769230769,110.81538461538462,112.58846153846154,114.36153846153846,116.13461538461539,117.90769230769232,119.68076923076923,121.45384615384616,123.22692307692307,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,101.95,102.175,102.4,102.625,102.85000000000001,103.075,103.3,103.525,103.75,103.975,104.2,104.425,104.65,{"y":104.875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,101.95,100.56923076923077,99.18846153846154,97.8076923076923,96.42692307692307,95.04615384615384,93.66538461538462,92.28461538461539,90.90384615384616,89.52307692307693,88.1423076923077,86.76153846153846,85.38076923076923,{"y":84,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.54,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.96,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.15,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.88,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.26,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.22,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.85,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.54,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.95,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$125.00

Average Price Target$104.88

Lowest Price Target$84.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Cooper

Raymond James

$105→$125

Buy

19.05%

Upside

Reiterated

09/03/26

Haemonetics price target raised to $125 from $105 at Raymond JamesHaemonetics price target raised to $125 from $105 at Raymond James

David Rescott

Robert W. Baird

$96→$119

Buy

13.33%

Upside

Reiterated

08/21/26

Haemonetics price target raised to $119 from $96 at BairdHaemonetics price target raised to $119 from $96 at Baird

Michael Petusky

Barrington

$95→$118

Buy

12.38%

Upside

Reiterated

08/19/26

Haemonetics price target raised to $118 from $95 at BarringtonHaemonetics price target raised to $118 from $95 at Barrington

Michael Matson

Needham

―

Hold

―

Reiterated

08/18/26

Haemonetics: CSL Plasma Migration Deal Highlights Long-Term Upside but Near-Term Risk/Reward Keeps Rating at Hold

Travis Steed

Bank of America Securities

$1→$120

Buy

14.29%

Upside

Assigned

08/18/26

Haemonetics price target raised to $120 from $100 at BofAHaemonetics price target raised to $120 from $100 at BofA

Joanne Wuensch

Citi

$92

Hold

-12.38%

Downside

Reiterated

08/13/26

Haemonetics (HAE) Receives a Hold from Citi

Anthony Petrone

Mizuho Securities

$90→$95

Buy

-9.52%

Downside

Reiterated

08/11/26

Mizuho Securities Reaffirms Their Buy Rating on Haemonetics (HAE)

Allen Gong

J.P. Morgan

$86

Hold

-18.10%

Downside

Reiterated

08/10/26

J.P. Morgan Sticks to Its Hold Rating for Haemonetics (HAE)

Marie Thibault

BTIG

$84

Buy

-20.00%

Downside

Reiterated

06/26/26

Analysts Conflicted on These Healthcare Names: Haemonetics (NYSE: HAE) and Health Catalyst (NASDAQ: HCAT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Cooper

Raymond James

$105→$125

Buy

19.05%

Upside

Reiterated

09/03/26

Haemonetics price target raised to $125 from $105 at Raymond JamesHaemonetics price target raised to $125 from $105 at Raymond James

David Rescott

Robert W. Baird

$96→$119

Buy

13.33%

Upside

Reiterated

08/21/26

Haemonetics price target raised to $119 from $96 at BairdHaemonetics price target raised to $119 from $96 at Baird

Michael Petusky

Barrington

$95→$118

Buy

12.38%

Upside

Reiterated

08/19/26

Haemonetics price target raised to $118 from $95 at BarringtonHaemonetics price target raised to $118 from $95 at Barrington

Michael Matson

Needham

―

Hold

―

Reiterated

08/18/26

Haemonetics: CSL Plasma Migration Deal Highlights Long-Term Upside but Near-Term Risk/Reward Keeps Rating at Hold

Travis Steed

Bank of America Securities

$1→$120

Buy

14.29%

Upside

Assigned

08/18/26

Haemonetics price target raised to $120 from $100 at BofAHaemonetics price target raised to $120 from $100 at BofA

Joanne Wuensch

Citi

$92

Hold

-12.38%

Downside

Reiterated

08/13/26

Haemonetics (HAE) Receives a Hold from Citi

Anthony Petrone

Mizuho Securities

$90→$95

Buy

-9.52%

Downside

Reiterated

08/11/26

Mizuho Securities Reaffirms Their Buy Rating on Haemonetics (HAE)

Allen Gong

J.P. Morgan

$86

Hold

-18.10%

Downside

Reiterated

08/10/26

J.P. Morgan Sticks to Its Hold Rating for Haemonetics (HAE)

Marie Thibault

BTIG

$84

Buy

-20.00%

Downside

Reiterated

06/26/26

Analysts Conflicted on These Healthcare Names: Haemonetics (NYSE: HAE) and Health Catalyst (NASDAQ: HCAT)

Stocks with the Highest Top Analyst Consensus in the General Sector

STDNStandard Nuclear

SKHYSK Hynix

ITGITG Inc. Class A

LIMENeutron Holdings, Inc.

EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Haemonetics

3 Months

Anthony PetroneMizuho Securities

Success Rate

21/42 ratings generated profit

Average Return

+1.23%

Copying Anthony Petrone's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +1.23% per trade.

1 Year

Anthony PetroneMizuho Securities

Success Rate

25/42 ratings generated profit

Average Return

+10.67%

Copying Anthony Petrone's trades and holding each position for 1 Year would result in 59.52% of your transactions generating a profit, with an average return of +10.67% per trade.

2 Years

Michael PetuskyBarrington

Success Rate

28/45 ratings generated profit

Average Return

+16.17%

Copying Michael Petusky's trades and holding each position for 2 Years would result in 62.22% of your transactions generating a profit, with an average return of +16.17% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HAE Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HAE has received 12 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. HAE average Analyst price target in the past 3 months is 104.88.

Each month's total comprises the sum of three months' worth of ratings.

HAE Financial Forecast

HAE Earnings Forecast

Next quarter’s earnings estimate for HAE is $1.29 with a range of $1.21 to $1.37. The previous quarter’s EPS was $1.14. HAE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year HAE has Performed in-line its overall industry.

HAE Sales Forecast

Next quarter’s sales forecast for HAE is $345.03M with a range of $338.00M to $354.73M. The previous quarter’s sales results were $339.38M. HAE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year HAE has Performed in-line its overall industry.

HAE Stock Forecast FAQ

What is HAE’s average 12-month price target, according to analysts?

Based on analyst ratings, Haemonetics Corp.’s 12-month average price target is 104.88.

What is HAE’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for HAE, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HAE a Buy, Sell or Hold?

Haemonetics Corp. has a consensus rating of Moderate Buy which is based on 6 buy ratings, 3 hold ratings and 0 sell ratings.

What is Haemonetics Corp.’s price target?

The average price target for Haemonetics Corp. is 104.88. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $125.00 ,the lowest forecast is $84.00. The average price target represents -0.12% Decrease from the current price of $105.

What do analysts say about Haemonetics Corp.?

Haemonetics Corp.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of HAE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Haemonetics (HAE) Stock Forecast & Price Target

HAE Analyst Ratings

HAE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Haemonetics

HAE Analyst Recommendation Trends

HAE Financial Forecast

HAE Earnings Forecast

HAE Sales Forecast

HAE Stock Forecast FAQ

Detailed List of Analyst Forecasts